About US
Contact us
-
Pharma cash rolls into Congress to defend an embattled industryIn the heat of the most ferocious battle over drug prices in years, pharmaceutical companies are showering U.S. senators with campaign cash as sweeping legislation heads toward the floor. In the firs2019/8/28
-
Novartis earlier acknowledged Zolgensma data errors to FDA but blamed them on poor reportingIn an inspection of the Illinois manufacturing facility for Novartis’ Zolgensma earlier this year, a team of top FDA officials met with AveXis staff. Although the assay that is now at the center of N2019/8/28
-
J&J found liable in Oklahoma opioid case and ordered to pay $572M; pledges to appealJohnson & Johnson fought hard against Oklahoma's claims the company played a "kingpin" role in the state’s opioid epidemic, but its lawyers fell short in those efforts after a six-week trial.On M2019/8/27
-
Can Lilly JAK Olumiant, plagued by side effects, really challenge Dupixent in dermatitis?Eli Lilly and Incyte's Olumiant has run up against safety hurdles in the past.But can those hurdles stop the drugmakers fromadding another feather to the drug’s cap, this time in the booming—and incr2019/8/27
-
Don't give up yet on biosimilars, Gottlieb says. Congress could give them a boostIt’s no secret biosimilars haven’t made a big dent in U.S. drug spending. Some experts have even saidit’s time to give up on copycat biologics. But former FDA commissioner Scott Gottlieb argues it’s2019/8/26
-
FibroGen founder Neff dies suddenly as drug he championed racks up milestonesAfter founding FibroGen in 1993 and leading the company for 26years, chairman and CEO Thomas B. Neff passed away over the weekend unexpectedly. His death comes as FibroGen nears the critical U.S. and2019/8/26
-
Amgen, maker of Enbrel, to pick up Celgene's Otezla for $13.4B. Will FTC hit back?Looks like Amgen might not be buying Alexion Pharmaceuticals after all. Instead, it’s beefing up in psoriasis, where it already sells blockbuster TNF inhibitor Enbrel. Amgen Monday said it willtake i2019/8/23
-
Does Novartis' delay in probing data manipulation claims spell trouble?Why did Novartis wait about two months before launching an internal probe into the alleged data manipulation surrounding gene therapy Zolgensma? That's what officials at the FDA want to know. After a2019/8/23
-
Should J&J owe billions for Oklahoma's opioid crisis? We'll find out MondayOpioiddrugmakersface thousands of lawsuits around the country, a mountain of them grouped in Cleveland’s federal court. But right now, it'sa Monday decision—in the first opioid case to make it to tri2019/8/22
-
Amgen-Alexion deal rumors resurface, to the delight of investors and analystsRumors that Amgen is looking to prop up its top and bottom lines by buying Alexion have been floating around for more than a year. Now, they’ve resurfaced, much to the delight of Wall Street analysts2019/8/22